Cited by 709Liver Disease and TransplantationSepsis Diagnosis and TreatmentAbdominal vascular conditions and treatments

Primary Prophylaxis of Spontaneous Bacterial Peritonitis Delays Hepatorenal Syndrome and Improves Survival in Cirrhosis

Open access
Fernández, Javier, Navasa, Miquel, Planas, Ramón, Montoliu, Silvia, Monfort, David, Soriano, German, Vila, Carmen, Pardo, Alberto +5 more·2007·Gastroenterology

Abstract

Background & aims Norfloxacin is highly effective in preventing spontaneous bacterial peritonitis recurrence in cirrhosis, but its role in the primary prevention of this complication is uncertain.Methods Patients with cirrhosis and low protein ascitic levels (<15 g/L) with advanced liver failure (Child-Pugh score > or = 9 points with serum bilirubin level > or = 3 mg/dL) or impaired renal function (serum creatinine level > or = 1.2 mg/dL, blood urea nitrogen level > or = 25 mg/dL, or serum sodium level < or = 130 mEq/L) were included in a randomized controlled trial aimed at comparing norfloxacin (35 patients) vs placebo (33 patients) in the primary prophylaxis of spontaneous bacterial peritonitis. The main end points of the trial were 3-month and 1-year probability of survival. Secondary end points were 1-year probability of development of spontaneous bacterial peritonitis and hepatorenal syndrome.Results Norfloxacin administration reduced the 1-year probability of developing spontaneous bacterial peritonitis (7% vs 61%, P < .001) and hepatorenal syndrome (28% vs 41%, P = .02), and improved the 3-month (94% vs 62%, P = .003) and the 1-year (60% vs 48%, P = .05) probability of survival compared with placebo.Conclusions Primary prophylaxis with norfloxacin has a great impact in the clinical course of patients with advanced cirrhosis. It reduces the incidence of spontaneous bacterial peritonitis, delays the development of hepatorenal syndrome, and improves survival.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2007.06.065

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Rifaximin has been reported to increase survival in advanced liver cirrhosis in several small trials.

    “Similar to norfloxacin, rifaximin has been noted to increased survival in patients with advanced liver cirrhosis in several small-scale trials92–95.”
  • Norfloxacin improves 3-month survival in advanced cirrhosis patients.

    “Clinical trials in patients with advanced cirrhosis have shown that long-term use of orally administered norfloxacin is safe, produces a marked reduction of gram-negative bacteria in the faecal microbiota109, reduces the 1-year probability of developing spontaneous bacterial peritonitis and hepatorenal syndrome and improves 3-month survival92.”
  • Norfloxacin reduces the 1-year probability of developing spontaneous bacterial peritonitis and hepatorenal syndrome.

    “Clinical trials in patients with advanced cirrhosis have shown that long-term use of orally administered norfloxacin is safe, produces a marked reduction of gram-negative bacteria in the faecal microbiota109, reduces the 1-year probability of developing spontaneous bacterial peritonitis and hepatorenal syndrome and improves 3-month survival92.”
  • Several small clinical studies suggest that norfloxacin and rifaximin increase survival in patients with liver cirrhosis.

    “Moreover, several small-scale clinical studies have suggested that antibiotics such as norfloxacin and rifaximin increase survival in patients with liver cirrhosis92–95.”
  • Long-term oral norfloxacin is safe in patients with advanced cirrhosis.

    “Clinical trials in patients with advanced cirrhosis have shown that long-term use of orally administered norfloxacin is safe, produces a marked reduction of gram-negative bacteria in the faecal microbiota109, reduces the 1-year probability of developing spontaneous bacterial peritonitis and hepatorenal syndrome and improves 3-month survival92.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 36 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Andreu M, Solá R, Sitges-Serra A, Alia C, Gallen M, Vila MC, Coll S, Oliver MI. Risk factors for spontaneous bacterial peritonitis. Gastroenterology 1993;104:1133-1138.

Cited by

Sorted by citations

Authors
Fernández, J., Navasa, M., Planas, R., Montoliu, S., Monfort, D., Soriano, G., Vila, C., Pardo, A., Quintero, E., Vargas, V., Such, J., Ginès, P., & Arroyo, V.
Affiliations
  • Hospital Clínic de Barcelona (ES)
  • Hospital Universitari Germans Trias i Pujol (ES)
  • Hospital de Sant Pau (ES)
  • Hospital Del Mar (ES)
  • Hospital Universitario de Canarias (ES)
Corresponding author
Navasa, Miquel
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2007-09
Volume
133
Issue
3
Pages
818-824
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2012746560
Cited by
709
References
36
Citations by year
2026: 6 · 2025: 13 · 2024: 23 · 2023: 37 · 2022: 28 · 2021: 43 · 2020: 39 · 2019: 42 · 2018: 42 · 2017: 37 · 2016: 34 · 2015: 55 · 2014: 48 · 2013: 31 · 2012: 46
FWCI
30.85
Type
journal article
Language
en
Open access
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Epidemiology › Sepsis Diagnosis and Treatment
  • Health Sciences › Medicine › Surgery › Abdominal vascular conditions and treatments
Keywords
spontaneous bacterial peritonitis, primary prophylaxis, norfloxacin, hepatorenal syndrome, liver cirrhosis, survival, renal dysfunction, antibiotic prophylaxis
MeSH terms
Aged, Anti-Infective Agents, Double-Blind Method, Female, Hepatorenal Syndrome, Humans, Liver Cirrhosis, Male, Middle Aged, Norfloxacin, Peritonitis, Risk Factors, Survival Analysis, Antibiotic Prophylaxis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review